Aberrant Expression of BTLA, CD160, SPN, TIM-3, VISTA and TIGIT in Chronic Lymphocytic Leukemia and Psoriasis Patients Compared to Healthy Volunteers

与健康志愿者相比,慢性淋巴细胞白血病和银屑病患者中BTLA、CD160、SPN、TIM-3、VISTA和TIGIT的表达异常

阅读:1

Abstract

BACKGROUND: Currently, much attention is focused on the interactions between the leukemic and psoriatic cells showing immunosuppressive activity within the microenvironment. METHODS: Our study assessed a collective mRNA expression pattern of crucial immuno-regulatory genes: BTLA, CD160, SPN, TIM-3, VISTA, TIGIT, by qRT-PCR, and performed a comparison in two different diseases, chronic lymphocytic leukemia (CLL) and psoriasis (Ps), referring to clinical characteristics. RESULTS: In Ps, all the studied gene expressions, except TIM-3, were higher than in HVs and all the studied gene expressions, except VISTA, were lower than in CLL. However, the expression of TIM-3, a checkpoint inhibitor, was higher in 0 stage of CLL and was lower in advanced stages of the disease, suggesting its possible diagnostic value. Expression of VISTA was higher in Ps than in HVs, as well as in CLL. It is noteworthy that BTLA, CD160 and SPN were overexpressed in CLL and Ps compared to HVs, suggesting its involvement in immune suppression in both diseases. CONCLUSIONS: Significant correlations between gene expressions of SPN and BTLA, SPN and TIGIT, CD160 and TIM-3, were observed, indicating a potential shared regulatory mechanism for immune responses which suggests their bidirectional regulatory role on the functioning of immune system cells, depending on the context of inflammatory or neoplastic conditions.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。